Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression.
about
Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosisThe influence of innate and adaptive immune responses on atherosclerosisB cells and humoral immunity in atherosclerosisOxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.HDL inhibits the effects of oxidized phospholipids on endothelial cell gene expression via multiple mechanismsAtheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccineImaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directionsAltered pancreatic islet function and morphology in mice lacking the Beta-cell surface protein neuroligin-2.Oxidative stress activates endothelial innate immunity via sterol regulatory element binding protein 2 (SREBP2) transactivation of microRNA-92aOxidative and reductive metabolism of lipid-peroxidation derived carbonyls.In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish.Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease.Beyond vascular inflammation--recent advances in understanding atherosclerosis.Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans.Emerging applications for zebrafish as a model organism to study oxidative mechanisms and their roles in inflammation and vascular accumulation of oxidized lipidsA purified MAA-based ELISA is a useful tool for determining anti-MAA antibody titer with high sensitivity.Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesionsAdaptive immunity in atherogenesis: new insights and therapeutic approaches.Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable anginaDevelopment and application of a nonradioactive binding assay of oxidized low-density lipoprotein to macrophage scavenger receptors.Novel Mechanistic Interplay between Products of Oxidative Stress and Components of the Complement System in AMD PathogenesisAtheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100.Malondialdehyde mediates oxidized LDL-induced coronary toxicity through the Akt-FGF2 pathway via DNA methylation.Zebrafish models of dyslipidemia: relevance to atherosclerosis and angiogenesis.Role of phospholipid oxidation products in atherosclerosis.Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases.Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.Natural Monoclonal Antibody to Oxidized Low-Density Lipoprotein and Aggregatibacter actinomycetemcomitans.Cardiovascular Gene Therapy: Past, Present, and Future.Malondialdehyde Epitopes as Targets of Immunity and the Implications for Atherosclerosis.Cloning and expression of an anti-LDL(-) single-chain variable fragment, and its inhibitory effect on experimental atherosclerosis.Oxidized Low-Density Lipoprotein Loading of Macrophages Downregulates TLR-Induced Proinflammatory Responses in a Gene-Specific and Temporal Manner through Transcriptional Control.Copper sulfide nanoparticles as a photothermal switch for TRPV1 signaling to attenuate atherosclerosis.αMβ2 Is Antiatherogenic in Female but Not Male Mice.PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis.Relationship between oxidized LDL, IgM, and IgG autoantibodies to ox-LDL levels with recurrent cardiovascular events in Swedish patients with previous myocardial infarction.Oxidation-specific epitopes restrain bone formation.Oxidized phosphatidylcholines are produced in renal ischemia reperfusion injury.Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice
P2860
Q26822962-F36A4CE8-ACB1-4E31-80A8-07803295A3C9Q27000370-804BB841-FB25-46D9-BFDB-0F77C9C50CE3Q33789638-2578DA32-A058-4839-9AF9-CB3AC1942D3CQ33857831-534EA74F-9820-46D2-A056-9E18E7B04E33Q33945091-379004ED-B8F7-4BC6-BF2A-B06178325E8BQ34238712-3B266A8D-EE12-4CB8-99DF-106A2520AF96Q34518372-7C006C51-7F79-49B1-8127-9463C6DA2B89Q34775903-C5233846-E2AC-45B6-8D06-6A10934FE053Q35152219-00C1F46E-5403-41F1-A273-52CBFFC4A82EQ35554080-B7407F5A-BEF5-4CA0-9119-CC9218B75248Q35578606-33F81A9B-3A04-4FBE-BBA6-F2708E833D0AQ35789087-B64AE62C-450B-430F-914B-4398894D9CB5Q36020265-359884E5-AF6D-4F8E-A47A-CACB580B6778Q36079808-EA2E960E-A39D-42A2-878D-0BC0BB393772Q36239453-0A971F8D-026D-4D88-8873-EC07CBA77598Q36252515-AA109767-4997-4D10-81F1-4AD50CD5BC86Q36286506-AA3ED8F0-2346-4938-A54A-CA2BC7FB22DEQ36387263-8B504D91-CFC9-4078-A0C7-1B4C59F46FB6Q36497196-ADEC389E-F2B3-46D2-8530-63A3A1747E0FQ36739679-C2BD54A8-214D-4FDE-9F08-263EC207962BQ37222736-718B145F-2146-458B-9388-A6829A43B7BBQ37280091-780A197E-76E9-4986-9311-3C075F5EBC03Q37415733-9411F975-BDFB-4145-9EFC-F21426B4E2A6Q37596872-6DD028C4-D160-4A35-BAC2-EFB8A39E5C26Q37624675-EF5FABA6-6B73-462C-B8CB-EE6D7A761E18Q38039282-F70A9B67-4F9B-4475-A63F-292554CB5E49Q38222437-B4746C01-C3B9-4BF0-B761-237652A6E083Q38389141-3D4EB373-95AA-49C1-B64B-CEED19D76413Q38699093-1345E31D-D95B-47B5-BB19-5EEA2C68F215Q38733395-7242B919-35DD-420A-88E3-32447DA370D5Q38846881-271D6320-20D7-432C-A94B-C7014C5930A8Q39113883-5E7D08F2-FBB7-4938-87B1-7AC6AF071459Q42513358-34A5DE8B-5ED5-4821-996B-9BED3E3F01FCQ49272264-76C20E22-9F42-4C20-8AED-55CD9F734BB8Q49832779-33E65553-A94A-44FA-BF49-AFCE99C8C2B1Q49955253-3424647B-C7A3-40E8-9A4F-6AEE0E2F2288Q54518833-02AF535B-BCC5-4ABB-886D-EDCD119EB058Q55238725-386EA2A7-47D8-4E7F-8C46-4266597FBF21Q55431412-724851A5-A231-4442-A718-477B796C35CCQ59066080-0BEAE2B7-D935-4547-B427-98816C8258A1
P2860
Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Human oxidation-specific antib ...... d atherosclerosis progression.
@en
Human oxidation-specific antib ...... d atherosclerosis progression.
@nl
type
label
Human oxidation-specific antib ...... d atherosclerosis progression.
@en
Human oxidation-specific antib ...... d atherosclerosis progression.
@nl
prefLabel
Human oxidation-specific antib ...... d atherosclerosis progression.
@en
Human oxidation-specific antib ...... d atherosclerosis progression.
@nl
P2093
P2860
P1476
Human oxidation-specific antib ...... d atherosclerosis progression.
@en
P2093
Andrew C Li
Atsushi Miyanohara
Carole L Banka
Catherine A Reardon
Esther Merki
Godfrey S Getz
H Kirk Hammond
Janina Sollors
Jennifer Pattison
Karsten Hartvigsen
P2860
P304
P356
10.1016/J.JACC.2011.07.017
P407
P577
2011-10-01T00:00:00Z